https://doi.org/10.4081/ejtm.2024.12678
Research on the expression of Mir-218-2 in the serum of patients with papillary thyroid cancer and its clinical significance
Submitted: 19 May 2024
Accepted: 17 June 2024
Published: 29 August 2024
Accepted: 17 June 2024
Abstract Views: 0
PDF: 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Papillary thyroid carcinoma is an epithelial malignancy with follicular cell differentiation and sets of defined nuclear features and appearance of an irregular solid mass. The main objective of our study is to research on the expression of miR-218-2 in the serum of patients with papillary thyroid cancer and its clinical significance. Our study involved patients with thyroid nodules were divided into a capitate cancer group (N = 100) and a benign nodule group (N =100). Lastly, 50 cases of healthy individuals were used as controls. The total sample size was 250. All cases were clinically diagnosed and underwent histopathological examinations at the Tonglu County Hospital of Traditional Chinese Medicine between January 2023 and January 2024. Quantitative RT-PCR was used to assess the expression levels of miR-218-2 and its host gene SLIT3 in normal and cancer thyroid tissues. We found that 45% of tumour sizes were less than 1 cm with 90% of tumours did not infiltrate the glandular capsule, implying a favourable prognosis. Lastly, 85% of tumours were well differentiated with about 75% showing no metastasis while 60% of TNM stage were classified as stage I. Also, miR-218-2 and its host gene SLIT3 are significantly down-regulated in papillary thyroid carcinoma. The inhibitory effects of miR-218-2 act in synergy with its host gene SLIT3 to alter the rates of cell invasion, cell migration and cell proliferation. Our findings have clinical significance on the involvement of miR-218-2 and SLIT3. There exists a functional relationship between host genes and intronic miRNAs in the tumorigenesis of thyroid cancers.
Khan YS, Farhana A. Histology, Thyroid Gland. 2022 Dec 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31869123.
Censi S, Manso J, Mian C. Other markers of medullary thyroid cancer, not only calcitonin. Eur J Endocrinol 2023;188:R1-R13.
Hajeer MH, Awad HA, Abdullah NI, et al. The rising trend in papillary thyroid carcinoma: True increase or over diagnosis? Saudi Med J 2018;39:147-53.
Ito Y, Jikuzono T, Higashiyama T, et al. Clinical Significance of Lymph Node Metastasis of Thyroid Papillary Carcinoma Located in One Lobe. World J Surg 2006;30:1821-8.
Coca-Pelaz A, Shah JP, Hernandez-Prera JC, et al. Papillary thyroid cancer—aggressive variants and impact on management: a narrative review. Adv Ther 2020;37:3112-28.
Limaiem F, Rehman A, Mazzoni T. Papillary Thyroid Carcinoma. 2024 Mar 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30725628.
Han M, Chen L, Wang Y. miR-218 overexpression suppresses tumorigenesis of papillary thyroid cancer via inactivation of PTEN /PI3K/AKT pathway by targeting Runx2. OncoTargets Therapy 2018;11:6305-16.
Ha M, Kim VN. Regulation of microRNA biogenesis. Nature Rev Molecular Cell Biol 2014;15:509-24.
Broughton JP, Lovci MT, Huang JL, Yet al. Pairing beyond the Seed Supports MicroRNA Targeting Specificity. Molecular Cell 2016;64:320-33.
Vasudevan S. Posttranscriptional Upregulation by MicroRNAs. WIREs RNA. 2012;3:311-30.
Muhammad N, Bhattacharya S, Steele R, Ray RB. Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget 2016;7:58595-605.
Song H-M, Luo Y, Li D-F, et al. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells. Int J Clin Experiment Pathol 2015;8:9889-900.
Minna E, Romeo P, De Cecco L, et al. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Oncotarget 2014;5:2513-28.
Zhang J, Yang Y, Liu Y, et al. MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4. J Surg Res 2014;189:68-74.
Jia H, Sun W, Li X, Xu W. Melatonin promotes apoptosis of thyroid cancer cells via regulating the signaling of microRNA-21 (miR-21) and microRNA-30e (miR-30e). Bioengineered 2022;13:9588-601.
Lu W, Wan X, Tao L, Wan J. Long non-coding RNA HULC promotes cervical cancer cell proliferation, migration and invasion via miR-218/TPD52 axis. OncoTargets Ther 2020;13:1109-18.
Bevacqua E, Farshchi J, Niklison-Chirou MV, Tucci P. Role of MicroRNAs in the Development and Progression of the Four Medulloblastoma Subgroups. Cancers 2021;13:6323.
Koriyama T, Yamakuchi M, Takenouchi K, et al. Legionella pneumophila infection-mediated regulation of RICTOR via miR-218 in U937 macrophage cells. Biochem Biophys Res Comm 2019;508:608-13.
Guan H, Wei G, Wu J, et al. Down-Regulation of miR-218-2 and Its Host Gene SLIT3 Cooperate to Promote Invasion and Progression of Thyroid Cancer. J Clin Endocrinol Metab 2013;98:E1334-E44.
Tong M, Jun T, Nie Y, et al. The role of the slit/robo signaling pathway. J Cancer 2019;10:2694-705.
Jiang Z, Liang G, Xiao Y, et al. Targeting the SLIT/ROBO pathway in tumor progression: molecular mechanisms and therapeutic perspectives. Therapeutic Adv Med Oncol 2019;11:175883591985523.
Zhang T-J, Xu Z-J, Wen X-M, et al. SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm. Leukemia 2022;36:2488-98.
Sammarco ML, Tamburro M, Pulliero A, et al. Human papillomavirus infections, cervical cancer and MicroRNAs: an overview and implications for public health. MicroRNA 2020;9:174-86.
Dang S, Zhang R, Tian S, et al. MicroRNA‑218 inhibits the malignant phenotypes of glioma by modulating the TNC/AKT/AP‑1/TGFβ1 feedback signaling loop. Internat J Molecular Med 2021;48:205.
Liu Z, Mao L, Wang L, et al. miR‑218 functions as a tumor suppressor gene in cervical cancer. Mol Med Rep 2020;21:209-19.
Yin Z, Ren W. MicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatin. OncoTargets Ther 2019;12:759-71.
Tetzlaff MT, Liu A, Xu X, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocrine Pathol 2007;18:163-73.
Cahill S, Smyth P, Finn SP, et al. Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Molecular Cancer 2006;5:70.
Liu B, Shyr Y, Cai J, Liu Q. Interplay between miRNAs and host genes and their role in cancer. Briefings Functional Genomics 2019;18:255-66.
Venkataraman S, Birks DK, Balakrishnan I, et al. MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem 2013;288:1918-28.
Kinoshita T, Hanazawa T, Nohata N, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget 2012;3:1386-400.
Alajez NM, Lenarduzzi M, Ito E, et al. miR-218 Suppresses Nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 2011;71:2381-91.
Barzon L, Cappellesso R, Peta E, et al. Profiling of expression of human papillomavirus–related cancer miRNAs in penile squamous cell carcinomas. Am J Pathol 2014;184:3376-83.
Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Sci 2010;328:1566-9.
Van Rooij E, Quiat D, Johnson BA, et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Developmental Cell 2009;17:662-73.
Gonda Y, Namba T, Hanashima C. Beyond Axon guidance: roles of slit-robo signaling in neocortical formation. Front Cell Developmental Biol 2020;8:607415.
Krek A, Grün D, Poy MN, et al. Combinatorial microRNA target predictions. Nature Gen 2005;37:495-500.
Mavrakis KJ, Wolfe AL, Oricchio E, P et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nature Cell Biol 2010;12:372-9.
Nian R, Li W, Li X, et al. LncRNA MCM3AP-AS1 serves as a competing endogenous RNA of miR-218 to upregulate GLUT1 in papillary thyroid carcinoma. Arch Endocrinol Metab 2023;67:55-63.
Tie J, Pan Y, Zhao L, et al. MiR-218 Inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genetics 2010;6:e1000879.
Chen L, Hu N, Wang C, et al. Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression. Cell Cycle 2018;17:319-29. Retraction in: Cell Cycle 2023;22:1798.
Li P, Yang X, Cheng Y, et al. MicroRNA-218 Increases the sensitivity of bladder cancer to cisplatin by targeting Glut1. Cell Physiol Biochem 2017;41:921-32.
How to Cite
He, H., Hao, D., Tian, L., Zhu, C., Guo, L., Zhang, K., & Zhu, S. (2024). Research on the expression of Mir-218-2 in the serum of patients with papillary thyroid cancer and its clinical significance. European Journal of Translational Myology. https://doi.org/10.4081/ejtm.2024.12678
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.